(untitled)Christina Yau, Adam L. Asare, Jelle Wesseling et al.|Edinburgh Research Explorer|0Cited by 353
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M.S. Bartlett, Christopher Poole, Alison F. Munro et al.|The Lancet Oncology|2010Cited by 127
Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M.S. Bartlett, U Chetty, Jeremy Thomas et al.|Breast Cancer Research|2010Cited by 119
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative studyE. Jane Macaskill, J. Michael Dixon, John M.S. Bartlett et al.|Breast Cancer Research and Treatment|2010Cited by 55
Histological grading of invasive breast carcinoma – a simplification of existing methods in a large conservation series with long‐term follow‐upJeremy Thomas, John M.S. Bartlett, G.R. Kerr et al.|Histopathology|2009Cited by 32